ArticleFrontiers in cellular and infection microbiology2022
2'-Fucosyllactose inhibits proliferation of
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Engineered bacterial therapy suppresses Enterohemorrhagic Escherichia coli through metabolic competition and virulence silencing.Nature communications · 2026Article
- Characterization of the clade 4 non-toxigenicFEMS microbes · 2026Article
- 2'-Fucosyllactose inhibits human norovirus replication in human intestinal enteroids.Journal of virology · 2025Article
- Article
- Demonstration of phage inhibitory action againstFrontiers in antibiotics · 2025Article
- TranslatingFrontiers in microbiology · 2025Article
- Gastrointestinal complaints after Roux-en-Y gastric bypass surgery. Impact of microbiota and its metabolites.Heliyon · 2024Article
- Impact of Microbiota and Metabolites on Intestinal Integrity and Inflammation in Severe Obesity.Pharmaceuticals (Basel, Switzerland) · 2024Article
- 2'-Fucosyllactose Inhibits Human Norovirus Replication in Human Intestinal Enteroids.bioRxiv : the preprint server for biology · 2024Article
- Biological effects of combinations of structurally diverse human milk oligosaccharides.Frontiers in pediatrics · 2024Review
- A host-microbial metabolite interaction gut-on-a-chip model of the adult human intestine demonstrates beneficial effects upon inulin treatment of gut microbiome.Microbiome research reports · 2024Article
- Modeling the effects of prebiotic interventions on luminal and mucosa-associated gut microbiota without and withFrontiers in nutrition · 2024Article
- Animal and In Vitro Models as Powerful Tools to Decipher the Effects of Enteric Pathogens on the Human Gut Microbiota.Microorganisms · 2023Review
- Impact ofMicroorganisms · 2023Article
- Gut microbe-host interactions in post-COVID syndrome: a debilitating or restorative partnership?Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Results: Conclusion: The CDi-screen is suitable for studying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.